Inclusion criteria :

          -  At least 18 years of age or above (or countries legal age of maturity if above 18
             years) and signed the informed consent.

          -  Histologically or cytologically proven diagnosis of non-squamous NSCLC with metastatic
             disease at study entry; progression after platinum-based chemotherapy and immune
             checkpoint inhibitor.

          -  Participants with carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 5
             expression of ≥2+ in archival tumor sample (or if not available, fresh biopsy sample)
             involving at least 50 % of the tumor cell population as demonstrated prospectively by
             central laboratory via immune histochemistry (IHC).

          -  At least one measurable lesion by RECIST v1.1 as determined by local site investigator
             /radiologist assessment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  A female participant who agrees to use highly effective contraceptive methods during
             and for at least 7 months after the last dose of study intervention.

          -  A male participant who agrees to use highly effective contraception methods during and
             for at least 6 months after the last dose of study intervention.

        Exclusion criteria:

          -  Patients with untreated brain metastases and history of leptomeningeal disease. if
             previously treated brain metastases no documentation of non-progressive disease in
             brain by imaging performed at least 4 weeks after CNS directed treatment and at least
             2 weeks prior to the first dose of study intervention.

          -  Significant concomitant illnesses, including all severe medical conditions that would
             impair the patient's participation in the study or interpretation of the results.

          -  History within the last 3 years of an invasive malignancy other than the one treated
             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma
             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured
             by local treatment.

          -  Non-resolution of any prior treatment related toxicity to < grade 2 according to NCI
             CTCAE V5.0, except for alopecia, vitiligo and active thyroiditis controlled with
             hormonal replacement therapy

          -  History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known
             HIV disease requiring antiretroviral treatment, or unresolved viral hepatitis

          -  Previous history of and/or unresolved corneal disorders. The use of contact lenses is
             not permitted.

          -  Concurrent treatment with any other anticancer therapy.

          -  Prior treatment with docetaxel or maytansinoid derivatives (DM1 or DM4 antibody drug
             conjugate) or any drug targeting CEACAM5.

          -  Contraindication to use of corticosteroid premedication.

          -  Previous enrollment in this study and current participation in any other clinical
             study involving an investigational study treatment or any other type of medical
             research.

          -  Poor bone marrow, liver or kidney functions.

          -  Hypersensitivity to any of the study interventions, or components thereof (EDTA), or
             drug (paclitaxel, polysorbate 80) or other allergy that, in the opinion of the
             Investigator, contraindicates participation in the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.